Time：2025-06-30
(June 30, 2025 – Hong Kong) Medtide Inc. ("theCompany"; Stock Code: 3880) announced today that its shares commencedtrading on the Main Board of The Stock Exchange of Hong Kong Limited, with thestock code 3880. The successful listing of Medtide Inc. marks a keystep in the company's development process in the global pharmaceutical market.
Listing is not the end, but a new starting point:"In the future, we will consolidate our position in the globalpeptide-focused CRDMO industry and enhance the stability and reliability of ourglobal peptide-focused CRDMO service capabilities; strengthen our R&Dcapabilities and further upgrade our technologies to maintain our competitiveedge; further establish our global sales network to expand our customer base;strategically develop our oligonucleotide CDMO business and diversify ourservice portfolio; and continuously attract, retain, and develop talent."
Looking ahead, the Company willtake this listing as an opportunity to leverage global capital to further drivethe development of its business, and while achieving excellent performance,give back to shareholders, society, and the public!
About Medtide Inc.
Medtide Inc. is apeptide-focused contract research, development, and manufacturing organization(CRDMO), offering full-cycle services ranging from early-stage discovery,pre-clinical research and clinical development to commercial-stage production.The company is headquartered in Hangzhou, China, and has commercial productionbases and offices in both China and the United States. We have been deeplyinvolved in the peptide field for over 20 years. Today, we have become a CRDMOwith global operations and comprehensive service capabilities.
Medtide Inc. provides (i)contract research organization (CRO) services,namely peptide new chemicalentity (NCE) discovery synthesis; and (ii) contract development andmanufacturing organization (CDMO) services,namely peptide chemistry,manufacturing and controls (CMC) development and commercial manufacturing. Wehave established global operations, with projects covering over 50 countries,including major markets such as China, the United States, Japan, Europe, SouthKorea, and Australia. We provide our 1000+ customers with peptide drugdevelopment, production, and CMC documentation and filing support services thatmeet regulatory requirements in major markets worldwide.
As a trusted and sustainable enterprise, Medtide Inc. hasestablished long-term partnerships with many customers. Through closecollaboration, we assist customers in bringing drugs that profoundly impacthuman health to the market, focusing on patients and committed to improvingtheir lives, thus promoting the development of the human health industry.
